cisplatin + fluorouracil

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

5mo

AZN.L⭐Phase 3$217.4B

cisplatin + fluorouracil Phase 3 Results Expected

cisplatin + fluorouracil• Esophageal Squamous Cell Carcinoma640

Jun 2

00%

Drug Information

Target Indication

Esophageal Squamous Cell Carcinoma

Clinical Trial

Last updated: 1/7/2026

Developer

AZN.L

AstraZeneca PLC

Related Pipeline

Diabetes

Asthma

Non-small Cell Lung Cancer

Type 2 Diabetes Mellitus

Chronic Obstructive Pulmonary Disease (COPD)